Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study explores SARS-CoV-2 antibody responses in mild COVID-19 cases

by Medical Finance
in Coronavirus
Study: Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age. Image Credit: Zouls/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to medRxiv* preprint server, researchers evaluated antibody responses in mild cases of coronavirus disease 2019 (COVID-19).

Study: Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age. Image Credit: Zouls/Shutterstock
Study: Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age. Image Credit: Zouls/Shutterstock

Background

Currently, the risk of reinfection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) ranges from 0% to 19.5% for 10 months after infection, indicating that protective immunity develops and is sustained post-infection. Various studies in animal models and humans have revealed that antibodies and B and T lymphocytes are vital to the protection and immune memory. Further, the quantity and quality of these immune responses are pivotal to long-term immunity, but the underlying mechanisms remain unclear yet.

Age is an essential factor driving the outcome of diseases including COVID-19. Different studies have observed functional cellular and humoral responses among children against SARS-CoV-2 who primarily develop mild or asymptomatic disease. According to several reports, polyfunctional antibodies neutralize SARS-CoV-2 entry and recruit innate immune effectors such as neutrophils, complement systems, natural killer (NK) cells, and monocytes. These polyfunctional antibodies were inversely correlated with the severity of disease post-infection, indicative of diverse humoral responses.

Also, qualitative features are just as crucial as neutralizing responses and titers. Similarly, clusters of differentiation 4 (CD4) and CD8 T cell responses to SARS-CoV-2 are variable across people. Nevertheless, the factors driving the diverse immune responses against SARS-CoV-2 remain poorly defined.

The study and findings

The current study evaluated immune responses to COVID-19 and compared them as a function of age between non-hospitalized COVID-19 patients and healthy SARS-CoV-2-naïve subjects.

Ninety-one subjects from 45 households were recruited between June 2020 and March 2021, with each completing a survey for data on demographics, infection history, and clinical symptoms. Although 10 subjects required emergency services for illness, none were hospitalized. COVID-19 was confirmed in 67 participants by a polymerase chain reaction (PCR) test, spike (S) or nucleoprotein (N)-specific immunoglobulin G (IgG) detection, or viral RNA detection in plasma, while the remaining subjects had no evidence of COVID-19.

The humoral immune responses against SARS-CoV-2 were qualitatively and quantitatively profiled. The researchers estimated the plasma levels of IgG (IgG1 – IgG4), IgA (IgA1 and 2), and IgM specific to SARS-CoV-2 S and N proteins, and seasonal coronaviruses (CoVs) such as HKU1, OC43, NL63, and 229E. COVID-19 patients had significantly elevated levels of SARS-CoV-2-specific antibodies than controls, and no such differences (in antibody levels) were evident for seasonal CoVs. Most infected subjects neutralized pseudoviruses coated with SARS-CoV-2 D614G S protein, yet 29.8% of infected individuals had no neutralizing antibodies (nAbs).

Peripheral blood mononuclear cells (PBMCs) isolated from all subjects were stimulated in vitro with peptide pools of SARS-CoV-2 S, N, and matrix (M) proteins. Both CD4 and CD8 T cell activation-induced marker expression (AIM) was significant in infected participants compared to controls. CD4 T cell AIM responses remained stable for over six months in those who followed up. Some infected participants exhibited T cell responses despite no noticeable antibody responses.

Further, cytokine and chemokine responses were measured in peptide-stimulated PBMCs and compared to controls (non-stimulated PBMCs). In response to S and N but not M antigens, the secretion of interleukin (IL)-2 and interferon (IFN)-γ was Th1-biased in infected individuals. Increased age correlated strongly with increases in S-specific IgG1, nAbs, IL2, CD8 T cell activation, perforin, and granzyme B levels.

Further investigations revealed two distinct populations among those infected. Population 1 showed typical SARS-CoV-2 immune responses such as CD4+ AIM, IL2 secretion, antiviral antibody functions, and increased IgM levels to SARS-CoV-2 or seasonal CoVs. In contrast, population 2 demonstrated a non-classical, Th2-biased response like the secretion of IL4, IL10, and IL13, higher IgG2, and IgG4 to the receptor-binding domain (RBD) of S protein. Thirty-two COVID-19 patients were subsequently vaccinated with Pfizer, Moderna, or J & J vaccines. The team noted a significant boost in nAb levels post-vaccination, albeit a waning of immune responses with time was evident. Moreover, between the two populations, population 1 demonstrated higher post-vaccination nAb titers than population 2.

Conclusions

Based on the findings, the researchers noted that age and CD4+ Th1 responses were associated with qualitative features of humoral immunity against SARS-CoV-2. The immune responses were significantly diverse among the infected cohort, including some who did not develop nAbs. Age was significantly correlated to many immunological measures.

Age-associated immune responses against SARS-CoV-2 were mainly related to Ig isotypes produced during infection. To summarize the findings, humoral immune responses and effector functions to SARS-CoV-2 were shaped by age, COVID-19 severity, and CD4+ Th cell responses quality.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System. Image Credit: BaLL LunLa/Shutterstock

Comparing the Moderna and Pfizer-Biontech vaccines against SARS-CoV-2 infection

by Medical Finance
May 20, 2022
0

Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed to combat the ongoing coronavirus disease 2019...

Long-term exposure to air pollutants may increase the incidence of COVID-19

Long-term exposure to air pollutants may increase the incidence of COVID-19

by Medical Finance
May 20, 2022
0

Long term exposure to ambient air pollution may heighten the risk of COVID-19 infection, suggests research published online in the...

Study: Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. Image Credit: CROCOTHERY/Shutterstock

Unraveling the early host-immune response to SARS-CoV-2 in mild COVID-19 infections

by Medical Finance
May 20, 2022
0

In a study posted recently to the bioRxiv* preprint server, researchers determined the early immune response to severe acute respiratory...

Study: A method for variant agnostic detection of SARS-CoV-2, rapid monitoring of circulating variants, detection of mutations of biological significance, and early detection of emergent variants such as Omicron. Image Credit: Lightspring/Shutterstock

New method for monitoring circulating SARS-CoV-2 variants and detecting new ones

by Medical Finance
May 20, 2022
0

After more than two years of the coronavirus disease (COVID-19) pandemic, there is still a constant threat of evolving strains...

Providing recombinant antibody services and more within Europe

Providing recombinant antibody services and more within Europe

by Medical Finance
May 20, 2022
0

In this interview, News-Medical talks to Dr. Zhang Linlin, Technical Specialist at Sino Biological Europe, about their recombinant antibody services...

Study: Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. Image Credit: PhotobyTawat/Shutterstock

Withdrawing steroid treatment found to boost SARS-CoV-2 vaccine-induced immunity in kidney transplant recipients

by Medical Finance
May 20, 2022
0

In a recent study posted to the medRxiv* pre-print server, a team of researchers investigated the impact of the fourth...

Next Post
Scientists unravel how blood cells mount the first line of defense against viruses

Genome research explains why oats could be suitable for most people with celiac disease

Swapping single food item for a more planet-friendly alternative could reduce diet’s carbon footprint

First large-scale estimate of live microbes consumed by Americans daily

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Pandemic 620x480
    Study uncovers a series of natural products that can inhibit the main protease of SARS-CoV-2
  • Pandemic vulnerability index of US cities
    Which U.S. cities are most vulnerable to spread of COVID-19?
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply